CGSCogstate Limited

CGS Stock Price, Valuation & Chart | Cogstate Limited

Compare

$3.650+0.12 (+3.40%)

At close · 16 Oct 2026, 05:12 am

Sector: Healthcare Industry: Medical - Healthcare Information Services Website

Overview Financials Dividends Ratios

CGS Historical price chart

CGS Key Stats

Market Capitalization628.26M

PE Ratio35.85

EPS0.1

Trading Volume196.08K

Today's High/Low3.65/3.55

Dividend Yield0.79

52 Week High/Low3.98/1.75

Shares Outstanding172.13M

CGS Financial Statement

CGS Analyst ratings

Buy

Strong buy

Buy

Hold

Sell

Strong sell

Based on 3 analysts giving stock ratings to CGS in the past 3 months.

CGS Analysis & performance metrics

CGS Company profile

Cogstate Limited, a neuroscience technology company, provides computerized cognitive tests and electronic clinical outcome assessment solutions. The company's cognitive…

Cogstate Limited, a neuroscience technology company, provides computerized cognitive tests and electronic clinical outcome assessment solutions. The company's cognitive services include project management, data management, scientific consulting, statistical analysis, scales procurement, rater training, and monitoring solutions. It operates in Clinical Trials and Healthcare segments. The…

CGS Management team

Name

Position

Kristi GeddesCTO

General Counsel, Joint Company Secretary & Director

David James Franks BEc, C.A., F Fin, J.P.

Joint Company Secretary

Paul Maruff BBSc (Hons), Ph.D.

Founder & Chief Innovation Officer

Rachel Colite

Executive Vice President of Clinical Trials

Kenneth Billard

Chief Commercial Officer

Darren WatsonCFO

Chief Financial Officer

Kaycee Sink M.D.

Chief Medical Officer

Bradley John O'Connor B.Bus, C.A., CACEO

Chief Executive Officer, MD & Executive Director

Name

Position

Kristi GeddesCTO

General Counsel, Joint Company Secretary & Director

David James Franks BEc, C.A., F Fin, J.P.

Joint Company Secretary

Paul Maruff BBSc (Hons), Ph.D.

Founder & Chief Innovation Officer

Rachel Colite

Executive Vice President of Clinical Trials

Kenneth Billard

Chief Commercial Officer

Darren WatsonCFO

Chief Financial Officer

Kaycee Sink M.D.

Chief Medical Officer

Bradley John O'Connor B.Bus, C.A., CACEO

Chief Executive Officer, MD & Executive Director

Management Team

Kristi GeddesCTO

General Counsel, Joint Company Secretary & Director

David James Franks BEc, C.A., F Fin, J.P.

Joint Company Secretary

Paul Maruff BBSc (Hons), Ph.D.

Founder & Chief Innovation Officer

Rachel Colite

Executive Vice President of Clinical Trials

Kenneth Billard

Chief Commercial Officer

Darren WatsonCFO

Chief Financial Officer

Kaycee Sink M.D.

Chief Medical Officer

Bradley John O'Connor B.Bus, C.A., CACEO

Chief Executive Officer, MD & Executive Director

Management

Kristi GeddesCTO

General Counsel, Joint Company Secretary & Director

David James Franks BEc, C.A., F Fin, J.P.

Joint Company Secretary

Paul Maruff BBSc (Hons), Ph.D.

Founder & Chief Innovation Officer

Rachel Colite

Executive Vice President of Clinical Trials

Kenneth Billard

Chief Commercial Officer

Darren WatsonCFO

Chief Financial Officer

Kaycee Sink M.D.

Chief Medical Officer

Bradley John O'Connor B.Bus, C.A., CACEO

Chief Executive Officer, MD & Executive Director

Total 8 executives

CGS Frequently asked questions

What is Cogstate Limited (CGS) Stock Price?

Current stock price of Cogstate Limited (CGS) stock is $3.650. The stock price is +3.40% higher in the session. The intraday range can be seen from this page. Volume of Cogstate Limited (CGS) stock is 196.08K.

Last updated at 16 Oct 2026, 05:12 am.

Why is the Cogstate Limited (CGS) stock price going up or down today?

The stock price of Cogstate Limited (CGS) can change with earnings, company news, and overall market sentiment. Cogstate Limited operates in the Healthcare / Medical - Healthcare Information Services market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Cogstate Limited stock expensive at its current price?

Whether Cogstate Limited looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for CGS on this page is 35.85. EPS on this page is 0.10. Compare those figures with peers and growth expectations before deciding if the current Cogstate Limited price is justified.

How has the stock price of Cogstate Limited (CGS) performed historically?

Historical performance for Cogstate Limited (CGS) is shown on the price chart on this page. Review multi-period moves alongside volume to see how CGS reacted to past earnings and market events.

Should I buy Cogstate Limited (CGS) stock, at this price?

Buying Cogstate Limited (CGS) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.